Related Experiment Video
Updated: Nov 3, 2025

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
Published on: June 11, 2015
Genomic Analysis of a Novel Phage Infecting the Turkey Pathogen Escherichia coli APEC O78 and Its Endolysin Activity
Sangsang Deng1,2, Qiang Xu3, Yajuan Fu1,2
1Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Abstract:
Due to the increasing spread of multidrug-resistant (MDR) bacteria, phage therapy is considered one of the most promising methods for addressing MDR bacteria. Escherichia coli lives symbiotically in the intestines of humans and some animals, and most strains are beneficial in terms of maintaining a healthy digestive tract. However, some E. coli strains can cause serious zoonotic diseases, including diarrhea, pneumonia, urinary tract infections, and hemolytic uremic syndrome. In this study, we characterized a newly isolated Myoviridae phage, vB_EcoM_APEC. The phage vB_EcoM_APEC was able to infect E. coli APEC O78, which is the most common MDR E. coli serotype in turkeys. Additionally, the phage's host range included Klebsiella pneumoniae and other E. coli strains. The genome of phage vB_EcoM_APEC (GenBank accession number MT664721) was 35,832 bp in length, with 52 putative open reading frames (ORFs) and a GC content of 41.3%. The genome of vB_EcoM_APEC exhibited low similarity (79.1% identity and 4.0% coverage) to the genome of Acinetobacter phage vB_AbaM_IME284 (GenBank no. MH853787.1) according to the nucleotide Basic Local Alignment Search Tool (BLASTn). Phylogenetic analysis revealed that vB_EcoM_APEC was a novel phage, and its genome sequence showed low similarity to other available phage genomes. Gene annotation indicated that the protein encoded by orf11 was an endolysin designated as LysO78, which exhibited 64.7% identity (91.0% coverage) with the putative endolysin of Acinetobacter baumannii phage vB_AbaM_B9. The LysO78 protein belongs to glycoside hydrolase family 19, and was described as being a chitinase class I protein. LysO78 is a helical protein with 12 α-helices containing a large domain and a small domain in terms of the predicted three-dimensional structure. The results of site-directed mutagenesis indicated that LysO78 contained the catalytic residues E54 and E64. The purified endolysin exhibited broad-spectrum bacteriolytic activity against Gram-negative strains, including the genera Klebsiella, Salmonella, Shigella, Burkholderia, Yersinia, and Pseudomonas, as well as the species Chitinimonas arctica, E. coli, Ralstonia solanacearum, and A. baumannii. An enzymatic assay showed that LysO78 had highly lytic peptidoglycan hydrolases activity (64,620,000 units/mg) against E. coli APEC O78, and that LysO78 had lytic activity in the temperature range of 4-85 °C, with an optimal temperature of 28 °C and optimal pH of 8.0, and was active at pH 3.0-12.0. Overall, the results suggested that LysO78 might be a promising therapeutic agent for controlling MDR E. coli APEC O78 and nosocomial infections caused by multidrug-resistant bacteria.
Insights
A novel phage, vB_EcoM_APEC, effectively targets multidrug-resistant Escherichia coli. Its endolysin, LysO78, shows broad-spectrum bacteriolytic activity, offering a promising therapeutic approach against resistant bacterial infections.
Area of Science:
- Microbiology
- Bacteriology
- Genomics
Background:
- Multidrug-resistant (MDR) bacteria pose a significant global health threat, driving the search for alternative therapies.
- Phage therapy, utilizing bacteriophages to combat bacterial infections, is emerging as a promising strategy against MDR strains.
- Escherichia coli (E. coli) is a common bacterium, with certain strains causing severe zoonotic diseases and contributing to MDR infections.
Purpose of the Study:
- To characterize a newly isolated Myoviridae bacteriophage, vB_EcoM_APEC, targeting multidrug-resistant E. coli APEC O78.
- To analyze the genome of vB_EcoM_APEC and identify potential therapeutic components, such as endolysins.
- To evaluate the bacteriolytic activity and enzymatic properties of the identified endolysin for potential therapeutic applications.
Main Methods:
- Isolation and characterization of bacteriophage vB_EcoM_APEC.
- Genome sequencing and analysis of vB_EcoM_APEC, including phylogenetic analysis and gene annotation.
- Purification and enzymatic characterization of the endolysin LysO78, including determination of its lytic activity spectrum, optimal conditions, and catalytic residues.
Main Results:
- Phage vB_EcoM_APEC demonstrated infectivity against E. coli APEC O78 and other E. coli strains, as well as Klebsiella pneumoniae.
- The vB_EcoM_APEC genome (35,832 bp) revealed a novel phage with low similarity to known phages. Gene orf11 encoded endolysin LysO78.
- LysO78 exhibited broad-spectrum bacteriolytic activity against Gram-negative bacteria, including MDR strains, with optimal activity at pH 8.0 and 28 °C.
Conclusions:
- Phage vB_EcoM_APEC represents a novel bacteriophage with potential for controlling MDR E. coli APEC O78.
- The endolysin LysO78 shows significant bacteriolytic properties, suggesting its utility as a therapeutic agent.
- LysO78 holds promise for combating multidrug-resistant bacterial infections, including nosocomial infections.
More Related Videos
Related Concept Videos
Viral Replication: Lytic Cycle
DNA Bacteriophages
Lysogenic Cycle of Bacteriophages

